IMRX
Immuneering Corporation
NASDAQ · Healthcare · Biotechnology · US
$4.82
−4.37%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.7x
Market Cap
$311.84M
MomentumView details →
1D Return
−4.37%
YTD Return
−25.61%
RSI (14)
48.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.7x
Market Cap
$311.84M
RSI (14)
48.6
MomentumView details →
1D Return
−4.37%
YTD Return
−25.61%
SummaryUpdated Jun 1, 2026
Immuneering Corporation (NASDAQ:IMRX) is a clinical-stage biopharmaceutical company founded in 2008 and headquartered in Cambridge, Massachusetts. Originally a subsidiary of Teva Pharmaceutical Industries, the company went public in July 2021. Immuneering focuses on developing novel cancer treatments that target specific cellular pathways involved in tumor growth, particularly the RAS/RAF/MEK pathway which is commonly mutated in various cancers.
Similar companies
Latest newsMore news →
Immuneering Corporation reported its financial results for the second quarter ended June 30, 2026, ending with $182.7 million in cash, cash equivalents and marketable securities with anticipated runway into 2029.31d agoImmuneering Corporation appointed Andrew Gengos as Chief Financial Officer, effective July 16.82d agoImmuneering (IMRX) began dosing the first patient in a pivotal Phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.85d ago